What is Onivyde
Onivyde is a novel drug that was approved by the FDA in October 2015 for the treatment of metastatic pancreatic cancer. It is a combination of the drugs irinotecan and 3- methyl-1- nitrosourea (3-M1NU), which are both already approved for the treatment of cancer. Onivyde is given as an intravenous infusion and is the first drug approved for the treatment of metastatic pancreatic cancer in over a decade.
Pancreatic cancer is a deadly disease with a five-year survival rate of only 6%. Metastatic pancreatic cancer is cancer that has spread to other parts of the body, and is the most advanced stage of the disease. There are few treatment options available for patients with metastatic pancreatic cancer, and the majority of patients die within months of diagnosis.
Onivyde is a novel drug that was approved by the FDA in October 2015 for the treatment of
Benefits of Onivyde
and Its Uses.
Onivyde is a pancreatic cancer drug manufactured by Merck Sharp and Dohme Corp. The drug was approved by the United States Food and Drug Administration (FDA) in October 2015 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have received prior chemotherapy.
Onivyde is a prodrug that is converted to the active drug irinotecan following administration. Irinotecan is a topoisomerase I inhibitor that interferes with the ability of the cancer cell to divide. The drug is administered intravenously (IV) over 90 minutes every two weeks.
Onivyde is indicated for the treatment of patients with metastatic adenocarcinoma of the pancreas who have received prior chemotherapy. The drug is not indicated for the initial treatment of patients with metastatic adenocarcinoma of the pancreas.
Side Effects and Dosage of Onivyde
Onivyde (irinotecan liposome injection) is a chemotherapy drug used to treat cancers of the pancreas, stomach, and intestines. It is a type of medication known as a topoisomerase inhibitor.
Onivyde is available as a capsule and an intravenous (IV) injection. The recommended dose of Onivyde is 70 mg/m2 administered as a 30-minute infusion on day 1 of each 3-week cycle.
Common side effects of Onivyde include diarrhea, nausea, vomiting, and abdominal pain. Serious side effects can include liver problems, blood clots, and heart problems.
Onivyde should not be used in people with a known allergy to irinotecan or any of the ingredients in Onivyde. It should also not be used in people with severe liver problems.
People taking Onivyde should avoid eating grapefruit and drinking grape